NCT04055467View on ClinicalTrials.gov

Brain Imaging in Tobacco Smokers During a Quit Attempt

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

October 30, 2022

Study Completion Date

November 30, 2022

Conditions
Tobacco Use DisorderTobacco Smoking
Interventions
DRUG

[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)

Brain imaging of alpha-7 nicotinic acetylcholine receptors

BEHAVIORAL

Contingency Management

Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits

Trial Locations (1)

21224

Elise Weerts, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT04055467 - Brain Imaging in Tobacco Smokers During a Quit Attempt | Biotech Hunter | Biotech Hunter